Royal Bank of Canada’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$66.1M Sell
944,457
-54,883
-5% -$2.84M 0.01% 853
2026
Q1
$50.8M Sell
999,340
-144,440
-13% -$6.74M 0.01% 908
2025
Q4
$33.7M Sell
1,143,780
-513,785
-31% -$14M 0.01% 1145
2025
Q3
$42.8M Sell
1,657,565
-1,212,848
-42% -$33.8M 0.01% 1101
2025
Q2
$79.2M Buy
2,870,413
+1,921,323
+202% +$50.6M 0.01% 724
2025
Q1
$26.9M Buy
949,090
+165,506
+21% +$5.87M 0.01% 1121
2024
Q4
$32.6M Buy
783,584
+153,617
+24% +$7.34M 0.01% 1051
2024
Q3
$42.1M Sell
629,967
-7,358
-1% -$676K 0.01% 902
2024
Q2
$75.7M Sell
637,325
-20,920
-3% -$2.65M 0.02% 611
2024
Q1
$70.1M Sell
658,245
-69,114
-10% -$6.97M 0.02% 655
2023
Q4
$72.3M Buy
727,359
+179,759
+33% +$15.1M 0.02% 626
2023
Q3
$56.6M Buy
547,600
+32,902
+6% +$3.67M 0.02% 646
2023
Q2
$62.5M Buy
514,698
+90,973
+21% +$12.1M 0.02% 623
2023
Q1
$65.1M Sell
423,725
-271,588
-39% -$44.8M 0.02% 590
2022
Q4
$125M Buy
695,313
+225,528
+48% +$36.9M 0.04% 413
2022
Q3
$55.6M Buy
469,785
+75,684
+19% +$11.5M 0.02% 607
2022
Q2
$56.3M Buy
394,101
+11,769
+3% +$1.68M 0.02% 623
2022
Q1
$65.9M Sell
382,332
-291,308
-43% -$49M 0.02% 648
2021
Q4
$171M Buy
673,640
+290,055
+76% +$84.8M 0.04% 365
2021
Q3
$148M Buy
383,585
+99,433
+35% +$36.7M 0.04% 376
2021
Q2
$66.8M Buy
284,152
+31,662
+13% +$5.66M 0.02% 617
2021
Q1
$33.1M Sell
252,490
-10,795
-4% -$1.56M 0.01% 938
2020
Q4
$27.5M Buy
263,285
+129,950
+97% +$13.1M 0.01% 1038
2020
Q3
$9.43M Buy
133,335
+22,681
+20% +$1.58M ﹤0.01% 1585
2020
Q2
$7.1M Buy
110,654
+8,824
+9% +$483K ﹤0.01% 1707
2020
Q1
$3.05M Buy
101,830
+18,322
+22% +$422K ﹤0.01% 2155
2019
Q4
$1.63M Sell
83,508
-9,141
-10% -$162K ﹤0.01% 3057
2019
Q3
$1.48M Sell
92,649
-39,768
-30% -$587K ﹤0.01% 3006
2019
Q2
$1.94M Buy
132,417
+19,828
+18% +$426K ﹤0.01% 2801
2019
Q1
$2.29M Sell
112,589
-24,760
-18% -$460K ﹤0.01% 2576
2018
Q4
$2.1M Buy
+137,349
New +$2.26M ﹤0.01% 2609

Other funds holding MRNA

Royal Bank of Canada's MRNA Position: Q2 2026 in Review

Royal Bank of Canada reduced its Moderna (MRNA) stake by 5.5% in Q2 2026, selling an estimated $2.84M and leaving 944,457 shares worth $66.1M. The position accounts for 0.01% of the portfolio, ranked #853.

Royal Bank of Canada first reported a position in MRNA in Q4 2018 and has held it in 31 quarters since. The position peaked at $171M in Q4 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Royal Bank of Canada held 944,457 shares of Moderna worth $66.1M as of Q2 2026.
  • Royal Bank of Canada sold 54,883 Moderna shares in Q2 2026, an estimated $2.84M.
  • Moderna made up 0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #853 holding.
  • Royal Bank of Canada first reported a position in Moderna in Q4 2018 and has held it in 31 quarters since.
  • Royal Bank of Canada's Moderna position peaked at $171M in Q4 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.